We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Diagnostic Test Accurately Detects Colorectal Cancer by Identifying Microbial Signature in Gut Bacteria

By LabMedica International staff writers
Posted on 05 Jun 2025

Colorectal cancer remains one of the deadliest and most common forms of cancer worldwide, with only 40% of cases diagnosed before metastasis. More...

Current screening methods, like colonoscopy, are invasive and resource-intensive, limiting early detection efforts. The link between the gut microbiome and colorectal cancer was first identified several years ago. Certain bacteria present in the gut microbiota have the capacity to interfere with human cellular processes and are believed to contribute to cancer development over time. In some instances, this is due to their production of toxins that can damage DNA, leading to mutations, one of the key drivers of cancer. This suggests that the gut microbiota may help create conditions that promote the onset of the disease. Researchers have been working toward using the gut microbiome as a clinical target for screening for colorectal cancer. This would ideally allow simple stool tests to be used for early detection of the disease in place of expensive procedures such as colonoscopies. Now, an international research team has identified a unique microbial signature in stool samples that could lead to a highly accurate, non-invasive screening test based on gut microbiome analysis.

The multidisciplinary study, coordinated by the University of Trento (Trento, Italy), drew on the team’s expertise in microbiology, computational biology, and oncology to explore the potential of gut metagenomics in cancer detection. The researchers discovered that a specific group of around a dozen bacterial species consistently appears in greater numbers in the guts of individuals with colorectal cancer. Among the well-known bacteria is Fusobacterium nucleatum, alongside others such as Parvimonas micra, Gemella morbillorum, and Peptostreptococcus stomatis. These bacteria are typically present in the mouths of healthy individuals, but their presence in stool samples appears to be strongly associated with colorectal cancer. This microbial signature, identified through gut metagenomic sequencing, achieved nearly 90% accuracy in distinguishing between healthy individuals and those with the disease. Notably, the presence and abundance of these bacteria also correlate with the cancer’s stage and anatomical location, offering additional clinical insights.

A critical component of this breakthrough was the application of a novel machine learning framework developed by the research team. The model interprets complex microbiome patterns in stool samples to predict cancer presence with high confidence. While the study primarily focuses on early detection, the microbial signature may also offer clues about disease mechanisms. Some of these bacteria may promote cancer development by producing DNA-damaging toxins, further underscoring the complex relationship between the microbiome and carcinogenesis. However, the researchers stress that even without establishing causality, the value of this tool as a screening method remains significant. If validated through future clinical trials, this approach could complement or partially replace invasive procedures, such as colonoscopies, by allowing their use only in high-risk individuals identified through microbiome screening. This would streamline cancer detection, improve patient comfort, and potentially enable earlier treatment.


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.